Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
MINNEAPOLIS, April 06, 2018 -- Inspire Medical Systems, Inc. ("Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Inspire has applied to list its common stock on the New York Stock Exchange under the ticker symbol “INSP.”
BofA Merrill Lynch and Goldman Sachs & Co. LLC are serving as joint lead book-running managers for the proposed offering. Guggenheim Securities, Stifel, and Wells Fargo Securities are acting as co-managers for the proposed offering.
The offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to this offering, when available, may be obtained from any of the following sources:
- BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or via email: [email protected]; or
- Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: [email protected].
A registration statement on Form S-1 relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire Medical Systems’ proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
Investor and Media Contact:
Bob Yedid
LifeSci Advisors
[email protected]
646-597-6989
